Company / Current Assets
Actinium Pharmaceuticals, Inc. Current Assets History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$49.4M
FY2025
5-year range
$49.4M / $110.9M
FY2021-FY2025
Trend
-33.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $111M in FY2022 to $49M in FY2025.
Based on SEC 10-K filings.
$49M in FY2025 with a 3-year CAGR of -23.6%.
Declined from $78M to $49M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -23.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s current assets has declined for 3 consecutive years.
- 3-year CAGR of -23.6%, indicating a declining trend.
- In FY2025, current assets decreased 33.7% year-over-year.
- Peak current assets was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $49.4M | -33.7% |
| FY2024 | $74.5M | -4.8% |
| FY2023 | $78.3M | -29.5% |
| FY2022 | $110.9M | +39.1% |
| FY2021 | $79.7M | +1186.4% |
| FY2011 | $6.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026